Small intestinal perforation caused by metastatic tumor necrosis after sorafenib (Nexavar®) therapy for advanced hepatocellular carcinoma

Sorafenib (Nexavar ® , BAY 43-9006) is a novel multikinase inhibitor that has been recently approved for the treatment of advanced hepatocellular carcinoma (HCC). The increased use of sorafenib has been accompanied by an increase in the number of reports on the adverse effects of this drug. Generall...

Full description

Saved in:
Bibliographic Details
Published in:International cancer conference journal 2012-07, Vol.1 (3), p.155-158
Main Authors: Choi, Jun-Ho, Kim, Tae Hyeon, Choi, Keum Ha, Oh, Hyo Jeong
Format: Article
Language:English
Subjects:
Angiogenesis
Case Report
Chemotherapy
Diarrhea
Diverticulitis
Drugs
Hepatocellular carcinoma
Intestine
Kinases
Liver cancer
Medicine
Medicine & Public Health
Metastases
Metastasis
Necrosis
Oncology
Patients
Radiation therapy
Risk factors
Side effects
Small intestine
Surgical Oncology
Tumors
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sorafenib (Nexavar ® , BAY 43-9006) is a novel multikinase inhibitor that has been recently approved for the treatment of advanced hepatocellular carcinoma (HCC). The increased use of sorafenib has been accompanied by an increase in the number of reports on the adverse effects of this drug. Generally, the adverse effects of sorafenib are well tolerated, and the most common drug-related toxicities are hand-foot skin reaction, diarrhea, fatigue, rash, and hypertension. Here, we report the case of a 54-year-old man who developed small bowel perforation 2 months after receiving sorafenib for advanced HCC. The exact pathogenesis of the perforation is unclear. The cause of small bowel perforation in this patient was most likely metastatic tumor necrosis due to sorafenib. From this case, we can infer that treatment with antiangiogenic multikinase inhibitors may be associated with gastrointestinal (GI) perforations. Physicians should keep the possibility of this rare but potentially serious GI complication related to sorafenib treatment in mind.
ISSN:2192-3183
2192-3183
DOI:10.1007/s13691-012-0030-5